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Strains of Streptococcus pyogenes from Severe Invasive Infections Bind
HEp2 and HaCaT Cells More Avidly than Strains from
Uncomplicated Infections
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Epidemiologically unrelated Streptococcus pyogenes strains isolated from blood, throat, and skin were assayed
for adherence to HEp2 and HaCaT cells. Invasive isolates showed significantly higher avidity for these cell lines
than isolates from skin and throat. In general, S. pyogenes showed greater binding to HaCaT cells than to HEp2
cells.
Streptococcus pyogenes (group A streptococcus [GAS]) is an
etiological agent for diverse human diseases, including phar-
yngitis, pyoderma, and severe invasive diseases. In addition,
the pathogen is associated with potentially life-threatening se-
quelae such as poststreptococcal glomerulonephritis and acute
rheumatic fever. In the Northern Territory (NT) of Australia
the incidence of acute rheumatic fever is very high among the
indigenous population (3), despite a low throat isolation rate
of GAS. Furthermore, pyoderma from GAS infection is ex-
tremely common and poststreptococcal glomerulonephritis is
endemic in many remote Aboriginal communities (4, 7). While
asymptomatic throat carriage is often the reported reservoir
for strains associated with invasive disease (5), in populations
where impetigo is endemic, such as in Aboriginal communities
in the NT, the primary reservoir is the skin. Irrespective of
which tissue is the primary site of infection, the first event the
pathogen needs to achieve is adherence to host cells. The S.
pyogenes genome encodes numerous genes that could be re-
garded as encoding adhesins. These genes are highly regulated,
and individual strains do not have the genetic potential to
encode all of these proteins. The adhesins include M protein
(an antiphagocytic molecule), capsule, and fibronectin binding
proteins. There are many different fibronectin binding pro-
teins, such as SfbI (8, 12), PrtF2 (9, 10), Fbp54 (2), and SfbII
(11). The adherence capacity of an individual strain could vary
depending on the repertoire of genes for the adhesins that the
strain possesses and their level of expression. This in turn may
reflect the differences in the ability to colonize and persistently
infect different tissue sites. A corollary of this is that isolates
from different tissue sites may exhibit differences in adherence
capacity. To test this, we have determined the extent of binding
of GAS isolates from skin, throat, and blood to HEp2 and
HaCaT cell lines, representing human laryngeal epithelial cells
and keratinocytes, respectively.
GAS isolates from the NT were collected between 1990 and
2002. The 72 strains analyzed in this study were isolated from
blood (n  26), skin (n  22), and throat (n  24) (Table 1).
Blood isolates were from severe disease, and the remaining
strains were from uncomplicated infections. The isolates were
Vir typed as described previously (6). Vir typing involves re-
striction fragment length polymorphism of the mga regulon,
which includes the gene for highly variable M protein. To
ensure inclusion of epidemiologically unrelated strains, one
representative isolate from each Vir type was included. Cul-
tures were grown overnight at 37°C in an orbital shaker to
stationary phase in Todd-Hewitt broth (Oxoid, Basingstoke,
United Kingdom) supplemented with 1% yeast extract. To
prepare the GAS inoculum for adherence assays, overnight
cultures were centrifuged, and the pellets were washed in phos-
phate-buffered saline (PBS; Life Technologies Gibco BRL,
New York, N.Y.) and resuspended in serum-free and antibi-
otic-free RPMI 1640 medium (Life Technologies) to an optical
density at 600 nm of 0.05. This represents approximately 1 
107 to 1.5  107 bacteria per ml.
Human laryngeal epithelial (HEp2) cells were maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum
(Life Technologies), 1% Fungizone (Life Technologies), 20 g
of vancomycin HCl (David Bull Laboratories, Sydney, Austra-
lia) per ml, and 100 g of streptomycin sulfate (Sigma, St.
Louis, Mo.) per ml. Human adult skin keratinocytes (HaCaT
cells) were maintained in Dulbecco’s modified Eagle medium
(Life Technologies) supplemented with 10% heat-inactivated
fetal calf serum. For adherence assays, 105 cells/ml were
seeded onto 12-mm-diameter glass coverslips in the bottoms of
24-well tissue culture plates (Nunc, Roskilde, Denmark). After
overnight growth at 37°C in 5% CO2 atmosphere, the cells
were washed with PBS (pH 7.4) and inoculated with 500 l of
the GAS inoculum. After 2 h of incubation at 37°C, the cov-
erslips were washed five times by adding 1 ml of PBS to each
well, and after gentle mixing, the wash solution was removed by
aspiration. After removal of the nonadherent bacteria, the host
cells and adherent bacteria were fixed with 95% methanol and
air-dried. After heat fixing, the coverslips were placed on slides
and Gram stained for viewing under oil immersion. In each
* Corresponding author. Mailing address: Queensland Institute of
Medical Research, 300 Herston Rd., Herston 4006, Australia. Phone:
61-7-33620407. Fax: 61-7-38453507. E-mail: sriS@qimr.edu.au.
3936
experiment, cells in several random fields were analyzed, and
attachment was expressed as the average number of GAS
chains per cell. All assays were performed in duplicate, and the
mean binding was determined for each strain. All statistical
analyses were performed with Stata Statistics/Data Analysis
program version 7.0 (Stata Corporation, College Station,
Tex.). Data were analyzed with t tests.
GAS strains adhered to both cell types, and the degree of
binding varied from strain to strain (Table 1). There was good
correlation between independent experiments with 20 isolates
repeated at two time intervals (data not shown), suggesting the
avidity of binding is reproducible and strain specific. Overall,
GAS binding to HaCaT cells is greater than to HEp2 cells (P
 0.05). When the data in Table 1 were separated based on the
tissue site of isolation, an average of 270 chains of GAS strains
from blood bound to 50 HaCaT cells (Fig. 1). In contrast, skin
and throat isolates bound on average only 169 and 178 chains
per 50 HaCaT cells, respectively. These differences are statis-
tically significant (P  0.0044 and 0.0063, respectively). Inter-
estingly, for HEp2 cells the differences are less pronounced
and not statistically significant. However, when the data were
reanalyzed based on invasive versus uncomplicated infections
by combining data for the skin and throat isolates, significant
differences between the two categories were found in both cell
lines (P  0.0011 for HaCaT; P  0.0238 for HEp2).
Earlier work from this laboratory showed that many com-
monly circulating strains of S. pyogenes could cause invasive
disease with skin as the primary site of infection (1). These
observations are consistent with the present findings of higher
avidity of the NT GAS strains for HaCaT than HEp2 cell lines
and blood isolates being able to bind in greater numbers than
the isolates from uncomplicated infections. Possible explana-
tions for the high adherence propensity of S. pyogenes blood
isolates include both genotypic and phenotypic differences be-
tween isolates from invasive and noninvasive disease sources.
Further studies are required to define the nature of this bind-
ing avidity and to determine whether it is consistent within
clonal populations.
We are indebted to D. Gordon and E. Giannakis for advice and for
providing HaCaT cells.
Funds from Cooperative Research Centre for Aboriginal and Trop-
ical Health supported this work.
FIG. 1. Comparison of binding of GAS to HaCaT and HEp2 cell
lines. Statistically significant results are indicated by asterisks. Error
bars represent standard errors.
TABLE 1. Vir type, binding, and source of isolation of GAS
isolates used in this study
Isolate Sourcea VTb
Binding toc:
HEp2 HaCaT
NS1 B 23 222 104.5  37.5
NS6 B 12.2 151.5  14.5 183
NS13 B 24 114.5  108 385  12
NS20 B 3.4 127.5  6.5 298  73
NS25 B 18 86.5  0.5 204  6
NS27 S 4 283  16 361.5  5.5
NS43 B 9 131.5  2.5 250.5  56.5
NS50 B 5 66.5  5.5 120  38
NS53 S 29.1 146.5  1.5 257.5  0.5
NS66 B 41.2 161.5  11.5 193  7
NS78 B 30 88.5  25.5 202.5  4.5
NS80 B 69 310 267.5  59.07
NS101 B 33.1 57.5  12.5
NS125 B 20.1 303.5  34.53
NS178 B 26 172.5  8.5 465.5  10.5
NS180 T 110 0 2.0  2.0
NS182 T 60 314 145.75
NS195 B 120 253 401  22
NS204 B 121 34.5  0.5 206  16
NS205 B 20.2 108.5  3.5 152  56
NS223 B 4 166  11 411  5
NS225 B 115 174.5  25.5 515.33
NS226 B 14.1 293 210  41.34
NS234 T 42.1 175  14 226  28
NS235 B 118 173  10 207  15
NS236 T 111 45  1 231.75
NS265 S 11 73  11 181  51
NS344 B 127 97  4
NS351 S 22 108
NS436 S 3.3 92  31 152
NS476 B 39 253.5  5.5 329  13
NS506 S 134 216.5  1.5
NS564 S 119 117.5  21.5 250  5
NS567 B 38 131.5  0.5 333.5  9.5
NS581 S 42 57  3 108.5  2.5
NS611 S 3.7 85  11 135.5  1.5
NS671 S 133 136.5  2.5 62  6
NS678 T 113 163.5  39.5 84
NS696 T 114 28  11
NS803 S 131 40  1 127  10
NS804 S 130 82  16 188.5  35.5
NS880 T 52 32  8 267.5  16.5
NS931 B 57 68.5  6.5 369  98
NS980 S 129 132.5  15.5 50.5  3.5
NS1030 S 77 94.5  19.5 112.5  10.5
NS1033 S 3.22 109.5  11.5 68.5  4.5
NS1045 S 117 50.5  3.5 54.5  10.5
NS1095 S 128 88.5  58.5 251.5  56.5
NS1096 S 32 40  1 122  34
NS1099 S 126 83  19 125  10
NS1107 T 33.3 285.5  13.5 159.5  18.5
NS1120 T 105 134  40 164
NS1122 S 65 74 129  1
NS1133 B 17.1 56.5  10.5 259  5
NS1140 B 101 147  5 122  66.52
NS1210 S 125 230  4 522
NS1215 T 316.5  6.5
NS1216 S 49.1 220 81  3
NS1350 T 17.5 70.5  8.14 299  3
3A T 14.3 50.5  14.33 50  36.8
11A T New 10.75  1.09 328.5  40.21
24A T New 99.83 228  78.89
30A T 3.6 130.5  0.5 329.33  51.55
51A T New 202  23.39
52A T 3.24 27.33  7.04 57.75  14.79
66A T 37.1 21.5  2.87 55.5  8.08
95A T 3.41 12.5  2.5 9.0
100A T 3.23 9  1 68  13.44
101A T 39.1 102  6 262.17  41.55
244op T New 33.75  12.5 186.5  28.66
CK232 T 3.5 119  14 261.5  11.5
CK410 T 28 73 184  7.0
Avg 117  78.6 208  119
a S, skin; B, blood; T, throat.
b VT, Vir type.
c Number of GAS bound per 50 HEp2 or HaCaT cells (mean  standard
deviation).
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